Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.
about
CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapyClinicopathological and prognostic characteristics of CD33-positive multiple myeloma.Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes.Computational design of a CNT carrier for a high affinity bispecific anti-HER2 antibody based on trastuzumab and pertuzumab Fabs.Targeting leukemia cells with gemtuzumab ozogamicin.Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.Receptor induction and targeted drug delivery: a new antileukaemia strategy.CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicinRecombinant immunotoxins for the treatment of haematological malignancies.Tumour-targeted chemotherapy with immunoconjugates of calicheamicin.CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.The role of gemtuzumab ozogamicin in acute leukaemia therapy.Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicinAnti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.Antibody-based therapy of leukaemia.Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy.Nanoparticles-mediated drug delivery approaches for cancer targeting: a review.Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.Antibody therapy for acute myeloid leukaemia.CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells.Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.Effect of monensin liposomes on the cytotoxicity of anti-My9-bR immunotoxin.Depletion of synovial macrophages in rheumatoid arthritis by an anti-FcgammaRI-calicheamicin immunoconjugate.Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo.Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin.
P2860
Q24678297-924DD026-2B87-41C3-978D-FBC979835509Q33371875-F2ACB610-0042-43A0-BEC2-ED4E6B090660Q33729158-066FB552-1066-4181-A82D-0534A7FB474EQ34435576-586D4200-5D42-46BE-A56A-39A237F0189FQ34473476-1E74E00E-5F6E-4431-B932-DF45E65358A3Q34566182-F835BCDF-4F51-4060-8B71-F37329C523DBQ35034815-B44C8B26-7553-4555-AC23-C69859E68939Q35164785-28C3DDD1-07BD-4F35-9EA8-D2596AA15F56Q35717808-4C9D4CAB-27D9-4F08-8D64-5C0B385C339BQ35842677-760C8FDD-B15A-4D86-9F58-1E3A8EC15C10Q35873771-E1132F43-9208-4AB5-9030-B3BCDF265C42Q35980938-16F44F75-CDBA-4051-903A-8D6C673D2013Q36367816-A95FA3C6-8215-45AD-9FC0-F555B9C70637Q36932014-40E644CE-7A25-427D-8BF7-A6B06F5E0BF1Q37381414-F43200ED-CF56-46A2-A237-5050EFA97245Q37512086-5997965C-6B44-4C72-A70E-829BA916EC20Q37605247-2D4F9EE2-5E82-43DC-9413-0B1CDF097048Q37818248-1A8B504D-5B04-4939-9F69-DDB1817F3E31Q38032893-51C4C9AB-6342-4283-A000-9824175CCA0EQ38109541-47888FC4-873F-4AF6-B715-9BB799128228Q38169814-C912E0A5-EC3F-4AAA-88E3-A061A3EBD4B9Q38355000-85570F87-4BDC-479D-A3D6-62D7C012C218Q39506455-6774A23E-0F2C-44BE-B3BA-DA66CDA6061EQ40616812-2D91FED0-0C30-477A-A2EC-2BB98171853DQ41282870-A403C6A1-F621-4D17-8B98-86901AE34156Q42166599-FDC8128B-3724-4843-80D8-1C01B2894FE5Q43048724-7E9E1F09-051F-44B2-9BC7-E22DD7157D8FQ45236184-FB8EFC66-E1AC-4914-A08E-1A55579145A3Q54329544-ACE8AB1C-748E-4193-92AE-0B4E725E1CD6
P2860
Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Calicheamicin-conjugated human ...... coprotein-expressing sublines.
@en
Calicheamicin-conjugated human ...... coprotein-expressing sublines.
@nl
type
label
Calicheamicin-conjugated human ...... coprotein-expressing sublines.
@en
Calicheamicin-conjugated human ...... coprotein-expressing sublines.
@nl
prefLabel
Calicheamicin-conjugated human ...... coprotein-expressing sublines.
@en
Calicheamicin-conjugated human ...... coprotein-expressing sublines.
@nl
P2093
P356
P1433
P1476
Calicheamicin-conjugated human ...... coprotein-expressing sublines.
@en
P2093
A Takeshita
S Fujisawa
S Nakamura
P2888
P304
P356
10.1038/SJ.LEU.2401851
P577
2000-08-01T00:00:00Z